A prospective study comparing patients with early and late relapsing pemphigus treated with rituximab - 18/06/18
Abstract |
Background |
Rituximab (RTX) is an effective therapy for patients with pemphigus; however, the therapy does not prevent relapse.
Objectives |
To compare early relapsing patients (before 12 months) and late relapsing patients (after 24 months) following RTX therapy.
Method |
In this prospective study, 19 patients were enrolled (14 with pemphigus vulgaris and 5 with pemphigus foliaceus). The baseline disease score, autoantibody levels, and percentage of CD20+ cells of patients with pemphigus were measured. Patients received 1 cycle of RTX and were followed for 26 months.
Results |
Among early relapsing patients (n = 5), the time to relapse was 6 to 11 months. Among late relapsing patients (n = 6), the time to relapse was 24 to 26 months. A significant difference was observed in the mean baseline anti–desmoglein 1 (DSG1) index between early relapsing (705.72) and late relapsing patients (210.4) (P = .0014). A significant negative correlation was found between the baseline anti-DSG1 index and time to relapse (r = −0.777, P = .00009).
Limitations |
The small number of patients with pemphigus foliaceus.
Conclusions |
Because patients with high baseline anti-DSG1 indices relapsed earlier, it may be important to follow these patients closely for the initial 12 months after RTX therapy. These patients may require a maintenance RTX dose during the first 12 months after RTX therapy.
Le texte complet de cet article est disponible en PDF.Key words : antidesmoglein antibodies, autoimmune bullous disease, pemphigus foliaceus, pemphigus vulgaris, relapse, rituximab
Abbreviations used : DSG, PDAI, PF, PV, RTX
Plan
| Funding sources: None. |
|
| Conflicts of interest: None disclosed. |
Vol 79 - N° 1
P. 97-103 - juillet 2018 Retour au numéro
Article précédent
- An assessment of the use of antihistamines in the management of atopic dermatitis
- Alice He, Steven R. Feldman, Alan B. Fleischer
- Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: Results from UNCOVER-1, UNCOVER-2, and UNCOVER-3
- Alexander Egeberg, Jashin J. Wu, Neil Korman, James A. Solomon, Orin Goldblum, Fangyi Zhao, Lotus Mallbris
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?